| Quarter | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
| 0 | 43 | 22 | |
Growth YoY Revenue Growth YoY% | |||
| 0 | 23 | 15 | |
| 0 | 20 | 6 | |
OPM OPM% | 45.6 | 28.4 | |
| 0 | 0 | 1 | |
Interest Expense Interest ExpenseCr | 0 | 2 | 1 |
Depreciation DepreciationCr | 0 | 1 | 1 |
PBT PBTCr | 0 | 17 | 5 |
| 0 | 4 | 1 | |
| 0 | 12 | 3 | |
Growth YoY PAT Growth YoY% | |||
NPM NPM% | 27.6 | 15.7 | |
| 0.0 | 12.9 | 565.1 |
| Quarter | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
| 0 | 43 | 22 | |
Growth YoY Revenue Growth YoY% | |||
| 0 | 23 | 15 | |
| 0 | 20 | 6 | |
OPM OPM% | 45.6 | 28.4 | |
| 0 | 0 | 1 | |
Interest Expense Interest ExpenseCr | 0 | 2 | 1 |
Depreciation DepreciationCr | 0 | 1 | 1 |
PBT PBTCr | 0 | 17 | 5 |
| 0 | 4 | 1 | |
| 0 | 12 | 3 | |
Growth YoY PAT Growth YoY% | |||
NPM NPM% | 27.6 | 15.7 | |
| 0.0 | 12.9 | 565.1 |
| Financial Year | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
Revenue RevenueCr | 38 | 43 | 65 |
Growth Revenue Growth% | 12.4 | ||
| 23 | 23 | 39 | |
| 15 | 20 | 26 | |
OPM OPM% | 40.0 | 45.6 | 39.9 |
| 0 | 0 | 1 | |
Interest Expense Interest ExpenseCr | 1 | 2 | 3 |
Depreciation DepreciationCr | 1 | 1 | 2 |
PBT PBTCr | 13 | 16 | 23 |
| 3 | 4 | 6 | |
PAT PATCr | 10 | 12 | 15 |
Growth PAT Growth% | 21.4 | ||
NPM NPM% | 25.6 | 27.6 | 23.6 |
| 10.6 | 12.9 | 578.0 |
| Financial Year | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
Revenue RevenueCr | 38 | 43 | 65 |
Growth Revenue Growth% | 12.4 | ||
| 23 | 23 | 39 | |
| 15 | 20 | 26 | |
OPM OPM% | 40.0 | 45.6 | 39.9 |
| 0 | 0 | 1 | |
Interest Expense Interest ExpenseCr | 1 | 2 | 3 |
Depreciation DepreciationCr | 1 | 1 | 2 |
PBT PBTCr | 13 | 16 | 23 |
| 3 | 4 | 6 | |
PAT PATCr | 10 | 12 | 15 |
Growth PAT Growth% | 21.4 | ||
NPM NPM% | 25.6 | 27.6 | 23.6 |
| 10.6 | 12.9 | 578.0 |
| Financial Year | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
Equity Capital Equity CapitalCr | 9 | 9 | 13 |
Reserves ReservesCr | 6 | 17 | 57 |
| 13 | 19 | ||
| 11 | 34 | ||
| 39 | 73 | 111 | |
| 31 | 55 | ||
| 8 | 19 | ||
| 39 | 73 | 111 |
| Financial Year | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
Equity Capital Equity CapitalCr | 9 | 9 | 13 |
Reserves ReservesCr | 6 | 17 | 57 |
| 13 | 19 | ||
| 11 | 34 | ||
| 39 | 73 | 111 | |
| 31 | 55 | ||
| 8 | 19 | ||
| 39 | 73 | 111 |
| Financial Year | Mar 2025 | Mar 2026 |
|---|---|---|
| -5 | -6 | |
| 0 | -2 | |
| 5 | 8 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 |
Free Cash Flow Free Cash FlowCr | -5 | -6 |
CFO To PAT CFO To PAT% | -46.7 | -50.8 |
CFO To EBITDA CFO To EBITDA% | -29.8 | -30.7 |
| Financial Year | Mar 2025 | Mar 2026 |
|---|---|---|
| -5 | -6 | |
| 0 | -2 | |
| 5 | 8 | |
Net Cash Flow Net Cash FlowCr | 0 | 0 |
Free Cash Flow Free Cash FlowCr | -5 | -6 |
CFO To PAT CFO To PAT% | -46.7 | -50.8 |
CFO To EBITDA CFO To EBITDA% | -29.8 | -30.7 |
| Financial Year | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|
Market Cap Market CapitalizationCr | 202 | ||
Price To Earnings Price To Earnings | 0.3 | ||
Price To Sales Price To Sales | 3.1 | ||
Price To Book Price To Book | 2.7 | ||
EV To EBITDA EV To EBITDA | 9.4 | ||
GPM GPM% | 47.6 | 56.5 | 56.5 |
OPM OPM% | 40.0 | 45.6 | 39.9 |
NPM NPM% | 25.6 | 27.6 | 23.6 |
ROCE ROCE% | 48.2 | 27.8 | 25.7 |
ROE ROE% | 66.5 | 44.8 | 21.9 |
ROA ROA% | 25.3 | 16.2 | 13.8 |
| Financial Year | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|
Market Cap Market CapitalizationCr | 202 | ||
Price To Earnings Price To Earnings | 0.3 | ||
Price To Sales Price To Sales | 3.1 | ||
Price To Book Price To Book | 2.7 | ||
EV To EBITDA EV To EBITDA | 9.4 | ||
GPM GPM% | 47.6 | 56.5 | 56.5 |
OPM OPM% | 40.0 | 45.6 | 39.9 |
NPM NPM% | 25.6 | 27.6 | 23.6 |
ROCE ROCE% | 48.2 | 27.8 | 25.7 |
ROE ROE% | 66.5 | 44.8 | 21.9 |
ROA ROA% | 25.3 | 16.2 | 13.8 |
| Market CapitalizationMkt CapCr | 233 | 232 | 205 | 202 | 198 | 177 | 154 |
| Close PriceClose₹ | 404.00 | 320.00 | 167.10 | 160.70 | 67.20 | 161.70 | 18.54 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 20.45 | 28.93 | 20.60 | 0.28 | 2.72 | 33.41 | 11.24 |
| Price To SalesPS | 2.29 | 4.73 | 2.43 | 3.12 | 2.51 | 6.98 | 0.59 |
| RevenueRevenueCr | 101 | 49 | 84 | 65 | 79 | 25 | 259 |
| Revenue Growth TTMRev Gr TTM% | 41.8% | 96.6% | 22.5% | -14.9% | 3.4% | 50.8% | |
| PAT Growth TTMPAT Gr TTM% | 16.6% | 83.2% | 33.6% | 421.4% | -29.6% | 20.1% |
| Market CapitalizationMkt CapCr | 233 | 232 | 205 | 202 | 198 | 177 | 154 |
| Close PriceClose₹ | 404.00 | 320.00 | 167.10 | 160.70 | 67.20 | 161.70 | 18.54 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 20.45 | 28.93 | 20.60 | 0.28 | 2.72 | 33.41 | 11.24 |
| Price To SalesPS | 2.29 | 4.73 | 2.43 | 3.12 | 2.51 | 6.98 | 0.59 |
| RevenueRevenueCr | 101 | 49 | 84 | 65 | 79 | 25 | 259 |
| Revenue Growth TTMRev Gr TTM% | 41.8% | 96.6% | 22.5% | -14.9% | 3.4% | 50.8% | |
| PAT Growth TTMPAT Gr TTM% | 16.6% | 83.2% | 33.6% | 421.4% | -29.6% | 20.1% |